A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer
Carol Aghajanian,Virginia L. Filiaci,Don S. Dizon,Jay W. Carlson,Matthew A. Powell,Angeles Alvarez Secord,Krishnansu S. Tewari,David Bender,David M. O’Malley,Ashley Stuckey,Jianjiong Gao,Fanny Dao,Robert A. Soslow,Heather A. Lankes,Kathleen N. Moore,Douglas A. Levine